Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
featured
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

lung cancer
lung carcinoma
growth factor
erlotinib
epidermal growth factor
  • 100 views
  • 23 Nov, 2020
  • 1 location
featured
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

  • 620 views
  • 08 Nov, 2020
  • 1 location
Tarceva Italian Lung Optimization tRial

The aim of this study is to assess the superiority of docetaxel in comparison to erlotinib in second line in wild-type EGFR tumour patients.

tarceva
docetaxel
erlotinib
EGFR
  • 39 views
  • 07 Nov, 2020
  • 47 locations
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

and erlotinib will be studied using intra-patient dose escalation for dose levels 1 and 2. These study agents will be administered orally until progression of disease, unacceptable toxicities

adjuvant chemotherapy
lung carcinoma
epidermal growth factor
pleural effusion
epidermal growth factor receptor
  • 12 views
  • 24 Jan, 2021
  • 1 location
Study of 3D Radiotherapy With or Without Erlotinib (Tarceva ) in Patients With Localized Non-Small Cell Lung Cancer

A phase II, multicenter, randomized trial of 3D Radiotherapy versus 3D Radiotherapy and erlotinib (Tarceva®) in patients with localized-unresectable (IA-IIIB) non-small cell lung cancer

tarceva
measurable disease
erlotinib
  • 3 views
  • 07 Nov, 2020
  • 1 location
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen

Erlotinib has demonstrated efficacy as a single agent in patients with NSCLC and the addition of erlotinib to chemotherapy has not achieved better results in the general population

kidney function test
secondary malignant neoplasm of liver
docetaxel
cancer chemotherapy
stage iv non-small cell lung cancer
  • 1 views
  • 07 Nov, 2020
  • 6 locations
Hydroxychloroquine and Gefitinib to Treat Lung Cancer

as ZD1839) and erlotinib (Tarceva ®, formerly known as OSI-774). Both are small molecule orally-bioavailable tyrosine kinase inhibitors (TKIs) of the EGFR TK domain, and have been shown to

epidermal growth factor
gefitinib
pleural effusion
tarceva
iressa
  • 39 views
  • 07 Nov, 2020
  • 1 location
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

kinase inhibitors (TKIs) such as Erlotinib and Gefinitib. The aim of this study is to compare the effects of Osimertinib alone versus SRS plus Osimertinib on intra-cranial disease control in EGFR

  • 50 views
  • 15 Mar, 2021
  • 15 locations
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression …

kinase inhibitor
epidermal growth factor
tarceva
docetaxel
epidermal growth factor receptor
  • 9 views
  • 07 Nov, 2020
  • 1 location
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment

1. Detection EGFR mutation of cancer cells from malignant pleural effusion. 2. Established the cancer cell lines with without EGFR mutation from malignant pleural effusion.

pleural effusion
EGFR
  • 7 views
  • 07 Nov, 2020